Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Assets Average: 2015-2025

Historic Assets Average for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $166.7 million.

  • CytomX Therapeutics' Assets Average rose 11.77% to $166.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.7 million, marking a year-over-year increase of 11.77%. This contributed to the annual value of $161.2 million for FY2024, which is 30.34% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Assets Average of $166.7 million as of Q3 2025, which was up 21.84% from $136.8 million recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Assets Average high stood at $418.3 million for Q2 2021, and its period low was $109.5 million during Q1 2025.
  • Its 3-year average for Assets Average is $177.6 million, with a median of $172.0 million in 2024.
  • Data for CytomX Therapeutics' Assets Average shows a peak YoY increase of 11.77% (in 2025) and a maximum YoY decrease of 43.33% (in 2025) over the last 5 years.
  • CytomX Therapeutics' Assets Average (Quarterly) stood at $355.3 million in 2021, then crashed by 31.42% to $243.7 million in 2022, then decreased by 13.22% to $211.5 million in 2023, then crashed by 38.64% to $129.8 million in 2024, then climbed by 11.77% to $166.7 million in 2025.
  • Its last three reported values are $166.7 million in Q3 2025, $136.8 million for Q2 2025, and $109.5 million during Q1 2025.